Immune checkpoint inhibition (PD-1 ± CTLA-4) with anti-EGFR demonstrated activity in previously treated colorectal cancer in two prior studies, with ORR 8% to 35% and median PFS 3.6 to 5.7 months (58, 59). This evidence concerns the gene EGFR and colorectal cancer.